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Abstract
We show that epigenome- and transcriptome-wide association studies (EWAS and TWAS) are prone to significant
inflation and bias of test statistics, an unrecognized phenomenon introducing spurious findings if left unaddressed.
Neither GWAS-based methodology nor state-of-the-art confounder adjustment methods completely remove bias
and inflation. We propose a Bayesian method to control bias and inflation in EWAS and TWAS based on estimation of
the empirical null distribution. Using simulations and real data, we demonstrate that our method maximizes power
while properly controlling the false positive rate. We illustrate the utility of our method in large-scale EWAS and TWAS
meta-analyses of age and smoking.
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Background
The large-scale analysis of epigenome and transcriptome
data in population studies is thought to answer fundamen-
tal questions about genome biology and will be instru-
mental in linking genetic and environmental influences
to disease etiology [1, 2]. Worldwide, research groups
are now joining forces to generate and analyze such data
[3–7] complementary to the vast resources of genetic data
that are already available and have been used successfully
in genome-wide association studies (GWAS). While the
analysis tool box for GWAS hasmatured, the development
of effective methodology for the analysis of epigenome-
and transcriptome-wide association studies (EWAS and
TWAS) is a nascent field of research. In an EWAS, DNA
methylation levels of typically hundreds of thousands of
CpG dinucleotides are individually tested for association
with an outcome of interest, while in a TWAS this is
done for expression levels of tens of thousands of genes.
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Currently, EWAS and TWAS analysis heavily relies on
approaches specifically designed for GWAS. However,
epigenome and transcriptome data are crucially differ-
ent from genetic data. They are quantitative measures
(and not discrete like genotypes) that are subject to major
confounding effects of technical batches and biological
influences, including cellular heterogeneity [2, 8]. Further-
more, molecular phenotypes such as DNA methylation
and gene expression often show stronger associations
with phenotypic traits or complex diseases than genotypic
markers.
A key aspect of the analysis of ome-wide association
studies is the control of test-statistic inflation. Inflation
of test statistics leads to an overestimation of the level
of statistical significance and dramatically increases the
number of false positive findings [9]. This has always been
a major concern in GWAS, but inflated test statistics are
also observed in EWAS [10, 11]. Often the level of infla-
tion exceeds that observed in GWAS, yet it is generally
not corrected [12]. In GWAS, test-statistic inflation is
commonly addressed using genomic control in which the
inflated test statistics are divided by the genomic inflation
factor. The genomic inflation factor estimates the amount
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of inflation by comparing observed test statistics across all
genetic variants to those expected under the hypothesis
of no effect [9]. Recent work pointed out crucial limita-
tions of genomic control in GWAS [13, 14]. Notably, the
genomic inflation factor was shown to provide an invalid
estimate of test-statistic inflation when the outcome of
interest is associated with many, small genetic effects [13].
In EWAS and TWAS, this is the rule rather than the
exception. Moreover, test statistics may not only be sub-
ject to inflation but also to bias [15], which is not corrected
for when using genomic control. Bias of test statistics leads
to a shift in the distribution of effect sizes and is driven by
confounding [16, 17], a prominent feature of EWAS and
TWAS but much less of a concern in GWAS [18]. Thus,
this calls for the development of new methods specifi-
cally designed to address test-statistic inflation and bias in
EWAS and TWAS analyses.
Although generally ignored, genomic control will over-
estimate the actual inflation unless it is estimated on
the basis of genetic variants not associated with the out-
come of interest [9, 19]. A Bayesian outlier model [20]
was proposed to solve this issue; it estimates inflation
while assuming a fixed and small number of 10 associ-
ated genetic variants. Although this is an improvement for
GWAS with few associations, it will not be sufficient to
solve the overestimation of inflation in EWAS and TWAS,
which typically yield substantially more associations. Nor
does it address the occurrence of test-statistic bias. In the
statistical literature, alternative methods have been pro-
posed in the context of large-scale multiple hypothesis
testing where an empirical null distribution is used for
inference [16, 21–23]. The utility of these approaches in
EWAS and TWAS, however, remains to be evaluated.
Here, we use simulation studies and large-scale methy-
lome (n = 2203) and transcriptome (n = 1910) data
[24, 25] to show that correcting inflated test statistics by
applying genomic control is too conservative for EWAS
and TWAS and that test-statistic bias cannot be ignored.
Moreover, we demonstrate that test-statistic bias and
inflation are represented by the mean and standard devi-
ation of the empirical null distribution and propose a
Bayesian method for its estimation. Application of state-
of-the-art batch correction methods, including SVA [26],
RUV [27], and CATE [17], were not able to remove all
test-statistic bias and inflation. Hence, the resulting test
statistics require empirical calibration to achieve opti-
mal statistical power while controlling the number of
false positives at the desired level. We develop a Bayesian
method for estimation of the empirical null distribution
and propose a bias and inflation correction implemented
as an R/Bioconductor [28, 29] package BACON. Finally,
we show the utility of ourmethod by performing an EWAS
and TWAS meta-analysis of two commonly studied out-
comes: age and smoking status.
Results
The genomic inflation factor is not suitable to measure
inflation in EWAS/TWAS
We performed an EWAS and TWAS of age and smoking
status using subsets of 500 individuals from two popu-
lation cohorts, namely the Leiden Longevity Study (LLS)
and LifeLines (LL) (Additional file 1: Table S1). The anal-
yses were adjusted for known technical and biological
covariates (including measured white blood cell counts)
within a linear model framework. Inflation of test statis-
tics was observed in all of the eight analyses (two cohorts,
two data types, and two outcomes; Fig. 1). The amount
of inflation estimated using the commonly used genomic
inflation factor [9] varied substantially across analyses and
ranged from 1.33 to 1.72 for the EWAS and from 1.21 to
1.54 for the TWAS (Fig. 1).
However, the genomic inflation factor appeared to be
correlated with the expected number of true associations.
For example, the genomic inflation factor was higher for
age than smoking status, and previous studies showed that
age is associated withmanymore differentially methylated
sites and differentially expressed genes than smoking sta-
tus [3–7]. For the analysis of age, the genomic inflation
factor was higher for LL than LLS, which can be attributed
to the higher statistical power for LL (age range 21 years)
than LLS (age range 9 years).
A simulation study substantiated the impression that the
genomic inflation factor depends on the number of true
associations (Fig. 2). In fact, this result can be derived
mathematically [9]. We conclude that the genomic infla-
tion factor commonly overestimates the true level of
test-statistic inflation in EWAS and TWAS.
EWAS/TWAS not only suffer from inflation but also from
test-statistic bias
While quantile-quantile plots of expected versus observed
test statistics, or their corresponding P values, are fre-
quently used to visualize inflation (Fig. 1), the alterna-
tive representation through a histogram of test statistics
reveals a second artifact, namely a bias of the test statis-
tics (Fig. 3a and Additional file 1: Figure S1). This bias
is visible as a deviation of the mode of the observed
test statistics from zero, which is the mode of the stan-
dard normal distribution. Since the majority of features
(being genetic variants, CpGs, or genes) are assumed not
to be associated with the outcome of interest, test statis-
tics obtained from a linear model should follow a standard
normal distribution (i.e., centered at zero). We observed
test-statistic bias in the EWAS and TWAS of age and
smoking irrespective of cohort and outcome (Additional
file 1: Figure S1). Genomic control does not address bias
because it uses a normal distribution with the mode fixed
at zero (Additional file 2). The misspecification of the
observed distribution of test statistics by genomic control
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Fig. 1 Inflated epigenome- and transcriptome-wide association studies. Quantile-quantile (QQ) plots for EWAS (panels a and b) and TWAS (panels c
and d) performed on the LifeLines (LL) and Leiden Longevity Study (LLS) cohorts for the phenotypes age and smoking status. Results for LL are
indicated in green and LLS in orange. QQ-plots show the observed minus log10-transformed P values obtained from a linear model corrected for
known biological and technical covariates against quantiles from the theoretical null distribution. Strong inflation, as estimated according to λχ21 [9],
was observed for both EWAS and TWAS of age, while for the EWAS and TWAS of smoking the amount of inflation is smaller (notice different y-axis
scales)
is illustrated in Fig. 3c. Note that even permutation-based
approaches, which are often assumed to rescue violations
of assumptions regarding the theoretical null distribution,
do not result in a proper null distribution, and both test-
statistic bias and inflation persist [16, 30] (Fig. 3d). We
mathematically derived that unobserved confounding fac-
tors introduce bias in the analysis of high-dimensional
data (Additional file 2), thus expanding on earlier work by
Rao [15].
Estimating test-statistic bias and inflation
Both bias and inflation represent deviations from the
theoretical null distribution: bias (i.e., mean), a devia-
tion from zero, and inflation (i.e., standard deviation)
(Additional file 2). Hence, estimating the amount of bias
and inflation is identical to estimating the parameters of
the empirical null distribution. We developed a Bayesian
method to estimate the empirical null distribution from
an observed set of test statistics and thus simultaneously
obtain estimates of bias and inflation. The method fits
a three-component normal mixture to the observed set
of test statistics using a Gibbs sampling algorithm [31].
One component reflects the null distribution with mean
and standard deviation representing bias and inflation.
The other two components with a positive and a negative
mean capture the fraction of true associations observed
in the data, which is assumed to be an unknown minority
of tests (Fig. 3b, Fig. 4, and Additional file 1: Figure S2).
Hence, our method simultaneously provides estimates for
the amount of bias and inflation without being affected by
an unknown proportion of true associations (Additional
file 1: Figure S3). We compared our method to alternative
approaches for estimation of the empirical null distri-
bution [16] in a simulation study. This showed that the

























Fig. 2 The genomic inflation factor overestimates inflation in the
presence of a moderate proportion of true associations. The box-plot
summarizes the estimated inflation for simulated data with different
amounts of true associations. One hundred sets of test statistics were
generated with different amounts of true associations (20%, 10% and
5%) but without any true inflation; i.e., the inflation factor should be
equal to one. The genomic inflation factor was calculated using
λχ21
[9]. A clear dependence on the number of true associations is
seen for the genomic inflation factor
performance of our method is equal to or better than
those of the previous methods under various scenarios.
Moreover, our method resulted in the most stable estima-
tion of the inflation, which suggests that other methods
randomly over- or underestimate the level of inflation
(Additional file 1: Figure S4 and Additional file 3).
Correction for unobserved covariates reduces test-statistic
bias and inflation
The primary causes of inflation and bias are thought
to be unmeasured technical and biological confounding
[8, 16], e.g., population substructure, batch effects, and
cellular heterogeneity. Various methods have been devel-
oped to reduce the impact of these unmeasured factors in
high-dimensional data [17, 26, 27, 32–34]. We applied six
of these methods to adjust an EWAS and TWAS of age
in 500 individuals, a subset of the LLS cohort, and inves-
tigated their impact on test-statistic bias and inflation.
All approaches reduced the amount of bias and inflation
as compared with a model using known covariates only
(Table 1 and Additional file 1: Table S2). Nevertheless,
residual bias and inflation were observed. Therefore, we
designed a two-stage method in order to preserve statis-
tical power while appropriately controlling the number
of false positives. First, we performed an analysis that
Fig. 3 Bias in transcriptome-wide association studies. Histogram of
test statistics from the TWAS of age in the LifeLines (LL) cohort. Each
panel shows a different null distribution. a Theoretical null (green):
normal distribution with mean and variance (0.0, 1.02), b empirical
null (brown): normal distribution with estimated mean and variance
using our Bayesian method (0.23, 1.52), c inflated null (purple): normal
distribution with zero mean and variance equal to the estimated
inflation estimated using the genomic control method (0.0, 1.52), and
d permutation null (pink): normal distribution with
permutation-based estimates of mean and variance (−0.006, 1.12).
For comparison the theoretical null (green) is shown in each panel
corrects for known biological and technical covariates
plus estimated unobserved covariates, followed by esti-
mating and adjusting the residual bias and inflation using
the empirical null distribution. In the adjustment step,
P values are calculated using the empirical null distribu-
tion instead of the standard normal or the inflated normal
that is used by the genomic control method. A complica-
tion of the genomic inflation factor is that it estimates the




) is required for genomic control on
normally distributed test statistics resulting from linear
models with a continuous outcome (here, DNA methyla-
tion and gene expression data). Furthermore, it is impor-
tant to note that bias not only results in incorrect test
statistics and P values but also results in biased estimates
of effect sizes. To evaluate the performance of the two-
stage method, we conducted a numerical simulation. To
account for unmeasured confounding, we selected CATE,
a state-of-the-art method that was shown to have supe-
rior performance in estimating unobserved covariates as
compared with alternative methods [17]. Our Bayesian
method in combination with CATE yielded the highest
power with the fraction of false positives close to the nom-
inal level (0.058±0.0052). In contrast, methods that ignore
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Fig. 4 Histogram of test statistics for TWAS on age (a and b) and smoking status (c and d) performed on two cohorts: LifeLines (LL) and Leiden
Longevity Study (LLS). The lines represent the three-component normal mixture fitted as estimated using our Bayesian method. The black line
represents the fit of the mixture, the red line the fit of the null component (the empirical null distribution with estimated mean and variance
reported). The blue and green lines represent the estimated fits of the alternative components (proportion of positively and negatively associated
features)
unobserved covariates led to high false positive rates and
methods that use genomic control resulted in low power
(Table 2). Also, the test-statistic calibration that has been
proposed to use in combination with CATE [17] was con-
servative, resulting in low power, which is in line with the
fact that this method is closely related to genomic control.
In addition to confounding, correlation between fea-
tures (i.e., CpGs and genes) may cause test-statistics infla-
tion or bias. A second simulation study showed that if
test statistics are correlated, our Bayesian method prop-
erly controls the false positive rate while preserving power
(Table 3). Again, the application of genomic control is too
conservative (Table 3 and Additional file 3).
Fixed-effect meta-analysis with control for bias and
inflation
A main development in the field of EWAS and TWAS,
analogous to current practice in GWAS, is the com-
bined analysis of multiple population studies to detect
an increasing number of associations including those
with small effect sizes. Fixed-effect meta-analysis com-
bines estimated effect sizes and their standard errors from
different studies to construct pooled estimates resulting in
higher precision of effect-size estimates and hence supe-
rior statistical power [35, 36]. We performed an EWAS
and TWAS of age and smoking status in four cohorts
totaling 2203 individuals with methylome and 1910
individuals with transcriptome data, respectively. We
combined the results from the four cohorts through fixed-
effect meta-analysis (Table 4 and Additional file 1: Figure
S5). As observed earlier, bias and inflation remained
present after addressing unmeasured confounding using
CATE. Also estimates of inflation using genomic control
were both higher and considerably more variable across
analyses and cohorts than the estimates obtained using
our Bayesianmethod (Table 4). The Bayesianmethod fully
removed all bias and inflation. Critically, bias (< |0.03|)
and inflation (< 1.14) remained minimal in the meta-
analysis as compared with a meta-analysis using genomic
control (Table 4). The latter contrasts to approaches in
which inflation is not addressed at all or those using
genomic control: both can result in high levels of inflation
and bias in the meta-analysis that often are consider-
ably higher than in the individual cohorts. The top hits
Iterson et al. Genome Biology  (2017) 18:19 Page 6 of 13
Table 1 Correction for unobserved covariates reduces
test-statistic bias and inflation
Method Genomic infl. factor Bayesian infl. factor (bias)√
λχ21
1. No 1.322 1.229 ( 0.000)
2. Known 1.237 1.169 ( 0.080)
3. PC (1) 1.257 1.183 ( 0.048)
4. PC (2) 1.222 1.147 (-0.002)
5. PC (3) 1.160 1.090 (-0.139)
6. SVA (3) 1.181 1.116 ( 0.022)
7. RUV-Res (3) 1.332 1.166 ( 0.086)
8. RUV-Emp (3) 1.197 1.130 ( 0.021)
9. CATE (2) 1.161 1.077 ( 0.053)
Genomic inflation factor estimates (
√
λχ21
, square root since the test statistics follow
a normal distribution and not a χ2) and inflation factor (and bias) estimates
obtained using the Bayesian estimation of the empirical null distribution from test
statistics obtained by fitting linear models for a TWAS of age in the Leiden Longevity
Study (LLS) cohort subset of 500 individuals. Nine different models were fitted using
different approaches to estimate and correct for unobserved covariates: (1) only
known covariates, (2) including known covariates, (3), (4), and (5) known covariates
plus one, two, or three principal component(s), respectively, (6) known covariates
plus three optimal surrogate variables estimated using SVA [26], (7) known
covariates plus three unobserved covariates estimated using RUV [32] with the
residual method, (8) known covariates plus three unobserved covariates estimated
using RUV [32] with the empirical method, (9) known covariates plus two optimal
latent variables estimated using CATE [17] (within parentheses the number of
principal components, optimal number of surrogate variables, or optimal number of
latent factors)
identified for age and smoking included those consis-
tently reported in previous studies [3–7]. Furthermore,
the simultaneous performance of an EWAS and TWAS
in a large-scale meta-analysis showed a remarkable over-
lap in results between the two study types of 410 and
Table 2 Bias and inflation correction after adjustment for
confounding factors yields optimal power
Method False positive rate Power
mean (stdev) mean (stdev)
No confounding adjustment
No correction 0.720 (0.0360) 0.720 (0.049)
Genomic control 0.001 (0.0020) 0.005 (0.007)
Bayesian control 0.029 (0.0076) 0.050 (0.018)
Confounding adjustment
No correction 0.060 (0.0056) 0.860 (0.037)
Calibration 0.030 (0.0042) 0.770 (0.053)
Bayesian control 0.058 (0.0052) 0.860 (0.041)
oracle 0.052 (0.0052) 0.850 (0.039)
Mean and standard deviation of the number of false positives and true positives
(power) for a simulation study repeated 100×. Data were generated according to the
simulation setup of Wang et al. [17]. The table summarizes the results for the naive
approach of no adjustment for confounding factors and adjusting for confounding
factors using CATE. Both in combination with different approaches are used to
control for inflation (and bias): no correction, correction using genomic control,
correction using the median and median absolute deviation (MAD), calibration [17],
and using our Bayesian method. As a comparison the oracle method is shown
where the simulated confounding factors have been added to the linear model
Table 3 Empirical null estimates from correlated test statistics
yield proper control of the false positives rate without any
reduction in power
Method False positive rate Power
mean (stdev) mean (stdev)
Uncorrelated
No correction 0.050 (0.003) 0.770 (0.020)
Genomic control 0.028 (0.003) 0.710 (0.020)
Bayesian control 0.052 (0.003) 0.770 (0.020)
Correlated
No correction 0.040 (0.030) 0.770 (0.020)
Genomic control 0.023 (0.006) 0.730 (0.090)
Bayesian control 0.054 (0.020) 0.800 (0.060)
Mean and standard deviation of the number of false positives and true positives
(power) for a simulation study repeated 100×. Correlated test statistics were
generated according to the simulation setup of Efron [51]. The table summarizes
the results for uncorrelated test statistics and correlated test statistics, without any
correction for inflation or bias, using genomic control and using our Bayesian
method
57 genes for age and smoking, respectively (assigning the
nearest gene to a CpG site) (Additional files 4–7: Tables
S3a-d). For example, both DNA methylation near and
expression of CD248, DNMT3A, and FBLN2 were asso-
ciated with age (Fig. 5a), while the same was true for
GPR15, AHRR and CLDND1 for smoking (Fig. 5b). In
total 15,967 (3.5%) CpG sites and 1020 (2.7%) genes were
significantly associated with age (Bonferroni-corrected
P values < 0.05). For smoking, the number of associ-
ated CpGs and genes were 1128 (0.25%) and 301 (0.80%),
respectively.
We implemented our Bayesian method as an
R/Bioconductor [28, 29] package BACON. BACON pro-
vides valid estimates of bias and inflation in large-scale
analyses including EWAS and TWAS, yields corrected
test statistics, and supports the streamlined application of
the method to fixed-effect meta-analyses.
Discussion and conclusion
We describe a novel Bayesian method to detect and
correct for bias and inflation in epigenome- and
transcriptome-wide association studies. Our method has
the crucial characteristic that it is largely independent of
the fraction of true associations in the data. We showed
that the application of genomic control results in spu-
rious associations because it does not address bias and,
moreover, reduces power because it is sensitive to the
number of true associations and thus commonly overes-
timates the levels of inflation. The performance of our
method towards estimating the empirical null distribution
of test statistics outperforms existing methods [16] by tak-
ing advantage of prior knowledge of the distribution and
the composition of test statistics.
Iterson et al. Genome Biology  (2017) 18:19 Page 7 of 13
Table 4 Bias and inflation of test statistics for EWAS and TWAS across four cohorts on age and smoking status
EWAS TWAS

















Uncorrected CODAM 1.17 0.100 (1.19) 1.02 0.040 (1.03) 1.13 -0.030 (1.20) 1.05 0.100 (1.06)
LL 1.45 -0.500 (1.94) 1.07 0.009 (1.08) 1.17 0.040 (1.39) 1.15 0.080 (1.22)
LLS 1.30 0.100 (1.36) 1.05 -0.200 (1.08) 1.18 0.050 (1.26) 1.15 -0.010 (1.17)
RS 1.34 0.700 (1.57) 0.99 -0.100 (1.01) 1.11 -0.005 (1.12) 1.10 -0.010 (1.12)
Corrected CODAM 1.01 -0.000 (1.01) 1.00 0.000 (1.01) 1.02 -0.010 (1.06) 1.00 0.000 (1.00)
LL 1.00 -0.000 (1.27) 1.00 0.000 (1.01) 1.02 0.010 (1.19) 1.02 0.010 (1.06)
LLS 1.02 0.007 (1.05) 1.00 -0.003 (1.01) 1.03 0.001 (1.07) 1.02 -0.010 (1.02)
RS 1.00 0.000 (1.02) 0.99 0.000 (1.01) 1.02 -0.006 (1.01) 1.01 0.001 (1.02)
1.19 -0.030 (1.47) 1.05 0.020 (1.10) 1.04 0.030 (1.28) 1.06 -0.002 (1.14)
meta-analysis
The table shows the bias and inflation as obtained using Bayesian method to estimate the empirical null and (within parentheses) using the genomic inflation factor(√
λχ21
)
both before correction and after correction for inflation (and bias in case of empirical control). The estimated inflation for the meta-analysis results are after control
for inflation and bias in the individual cohorts and (within parentheses) inflation after applying genomic control. Sample sizes of the cohorts for EWAS/TWAS were n=164/181
(CODAM), n=744/605 (LL), n=683/589 (LLS), and n=612/535 (RS)
Methods that try to estimate unmeasured covariates
[17, 26, 27] and those that try to recover the empirical
null distribution [16] rely on the same principle. They
extract information from features that are assumed not to
be associated with the outcome of interest. Methods to
estimate unknown covariates (e.g., RUV, SVA, and CATE
as we used here) either use negative controls or assume the
number of associated features to be sparse and, interest-
ingly, they can be unified in a single mathematical frame-
work [17]. Genomic control [9] yields a valid estimate of
the inflation factor when calculated from features that are
known not to be associated with the phenotype of interest.
Similarly, the estimation of the empirical null distribution
requires that the vast majority of features follow the null
distribution [16]. Our Bayesian method is designed to be
flexible in dealing with larger fractions of true associa-
tions, which turns out to be crucial in particular for EWAS
and TWAS meta-analyses.
Our work extends the work of Devlin and Roeder
[9], who originally propose to use genomic control to
tackle test-statistic inflation for GWAS, and links their
method to the pioneering work of Efron [16] on estimating
an empirical null distribution for high-dimensional data
inference. Hence, although specifically applied to EWAS
and TWAS, our statistical method may have implications
for any field focusing on statistical inference for high-
dimensional data, whether it be omics types or imaging
data.
Ourmethod of estimating bias and inflationmay resolve
a common inconsistency in the current analysis of EWAS
and TWAS. While it is becoming the norm to report
inflation factors calculated using the traditional genomic
control approach, inflation is rarely actually dealt with
in the analysis, presumably because this is deemed to be
too conservative. However, inflation may be substantial,
in particular in a meta-analysis, and current practice is
bound to introduce false positive findings. We show that
estimating the inflation factor using the genomic infla-
tion factor results both in an overestimation of the actual
inflation (i.e., it is indeed conservative) and in imprecise
estimates contributing to the previously unexplained, high
variability across studies. Our method provides a realistic
estimate of inflation that does not suffer from a high vari-
ability. Moreover, our method is the first to address the
previously unrecognized issue of bias in test statistics. In
conclusion, our method optimally reduces the number of
false positive findings while preserving statistical power
and can be seamlessly incorporated into existing work-




DNA methylation data and RNA-seq data were gener-
ated within the Biobank-based Integrative Omics Stud-
ies Consortium (http://wiki.bbmri.nl/wiki/BIOS_start-).
The data comprise four biobanks: Cohort on Dia-
betes and Atherosclerosis Maastricht (CODAM, n≈180)
[37], LifeLines (LL, n≈700) [38], the Leiden Longevity
Study (LLS, n≈600) [39], and the Rotterdam Study
(RS, n≈600) [40]. Sample identity of DNA methyla-
tion and gene expression data was confirmed using
genotype data. Both RNA-seq fastq files and DNA
methylation idat files are available from the European
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Fig. 5Manhattan plots meta-analyses across four cohorts of EWAS and TWAS of age and smoking status. Panel a shows the meta-analysis results of
the EWAS of age as − log10 P values and with reverse sign for the TWAS of age as log10 P values. Panel b shows the same figure for smoking. The
black line indicates 0.05 Bonferroni thresholds. Red gene names highlight the top 10 (nearest) genes resulting from the EWAS and TWAS. Black gene
names denote genes that were identified in both the EWAS and TWAS (genes for EWAS are the genes closest to the significant CpG)
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Genome-phenome Archive (EGA) under accession num-
ber [EGA:EGAC00001000277] together with pheno-
types and measured cell counts used in these analyses.
Data were generated by the Human Genotyping facil-
ity (HugeF) of ErasmusMC, the Netherlands (www.
glimDNA.org).
RNA-seq data preprocessing
A detailed description of the RNA-seq data processing
can be found in Zhernakova et al. [24]. Briefly, total RNA
from whole blood, depleted of globin transcripts, was
sequenced (2 × 50-bp) using the Illumina HiSeq 2000
platform, and read alignment was performed using STAR
(v2.3.0). Subsequently, RNA-seq counts were normalized
using TMM [41] and transformed to log2 counts per mil-
lion. Genes that yielded zero counts for all samples across
cohorts were removed, which resulted in 45,867 genes
(ENSEMBLv73). For all analyses, genes with the lowest
overall variance were excluded (5% lowest).
450K DNAmethylation data preprocessing
The generation of genome-wide DNA methylation data is
described by Bonder et al. [25]. Briefly, 500 ng of genomic
DNA was bisulfite modified using the EZ DNA Methyla-
tion kit (Zymo Research, Irvine, CA, USA) and hybridized
on Illumina 450K arrays according to the manufacturer’s
protocols. The original idat files were generated by the
Illumina iScan BeadChip scanner. Subsequently, sam-
ple quality control was performed using MethylAid [42].
Ambiguously mapped probes [43], probes with a high
detection P value (> 0.01), probes with a low bead count
(<3 beads), and probes with a low success rate (missing in
> 95% of the samples) were set to missing. Samples con-
taining an excess of missing probes (> 5%) were excluded
from the analysis. Subsequently, per cohort, imputation
[44] was performed to impute the missing values. Func-
tional normalization [45], as implemented in the minfi
package [46], was used per cohort. All analyses were per-
formed on M values. Detailed description of the 450K
DNA methylation preprocessing steps are available from
the git-repo Leiden450K [47].
White blood cell count prediction
White blood cell counts (WBC), i.e., neutrophils, lym-
phocytes, monocytes, eosinophils, and basophils, were
measured by the standard WBC differential as part of
the complete blood count (CBC). A minority of samples
were lacking CBCmeasurements. Since DNAmethylation
levels are informative of the white blood cell composition
[48], we build a linear predictor to infer the white blood
cell composition of those samples lacking WBC measure-
ments (Additional file 2). Predicted cell counts were used
in the meta-analysis. For the analyses of the cohort sub-
sets, individuals with measured cell counts were selected.
Association analyses
All association analyses were performed using limma’s
lmFit function [49]. Since the sample sizes of our data
were all above>100, the empirical Bayes step was skipped.
T test statistics were transformed to P values using a
standard normal distribution. For the analysis of RNA-
seq data, we first applied a voom-transformation [50] on
the TMM-normalized counts while controlling for known
covariates including age, gender, smoking statusmeasured
cell counts, and a technical covariate introducing a batch
effect (the flow-cell identifier of the sequencing machine).
For the analysis of DNA methylation data, the functional
normalized beta-values [45] were transformed to M val-
ues, and again lmFit was used to obtain test statistics
for the covariate of interest. Here we included age, gender,
smoking status, measured cell counts, and array position
as known covariates.
Genomic control and the genomic inflation factor
The genomic inflation factor as originally proposed by
Devlin and Roeder [9] is the ratio of the median of a
set of trend-test statistics (i.e., obtained by the Armitage’s
trend test that follows under the null hypothesis of no
association a χ2-distribution with one degree of freedom)
divided by the theoretical median, F−1
χ21
(1/2) = 0.456. For
example, let w1,w2, · · · ,wp be a set of p test statistics, fol-
lowing a χ21 -distribution with one degree of freedom; the
following estimator was proposed to quantify the amount
of inflation:
λχ21
= median{w1,w2, · · · ,wp}0.456 . (1)
Furthermore, it was proposed to control the inflated
test statistics by dividing the test statistics by the esti-
mated amount of inflation; this approach is referred to as
genomic control [9].
In EWAS/TWAS test statistics are usually obtained
from inference on the coefficients of linear regression
models (instead of a trend test), i.e., t-test statistics that
can be assumed approximately to follow a standard nor-
mal distribution (instead of a χ2-distribution). Therefore,
applying genomic control to these test statistics entails
dividing by the square root of the genomic inflation factor,√
λχ21
(instead of λχ21 ).
Estimation of the unobserved covariates
To investigate whether adding estimated unobserved
covariates reduces bias and inflation, we performed
EWAS/TWAS with (1) only the covariate of interest, (2)
known covariates (e.g., white blood cell counts), and either
(3) known covariates plus one, (4) plus two, or (5) plus
three principal components estimated from the data, and
(6) known covariates with estimated unobserved covari-
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ates using CATE [17]. For TWAS, we additionally used
RUV [27, 32] and SVA [26]. For EWAS, iSVA [33] and
RUVm [34] were used. All algorithms were used with
default parameters except for CATE, which was run using
calibrate=FALSE.
Simulation studies
The impact of true association on the genomic inflation factor
One hundred sets of 2000 test statistics were generated
from a normal mixture distribution with different mixture
coefficients (0.8, 0.90, and 0.95). The majority of the null
test statistics were drawn from a standard normal,N(0, 1),
while the alternative test statistics were drawn from a nor-
mal distribution, N(μ, 1), with μ ∼ N(0, 3). An equal
number of positive and negative associations were simu-
lated. For each set of test statistics, inflation factors were
calculated to investigate the impact of the number of true
associations (Additional file 3). Additional file 3 shows
the performance and robustness of BACON in estimat-
ing the empirical null distribution when different data
generating approaches are used.
Comparing differentmethods that estimate the empirical
null distribution
Efron proposed two methods for estimation of the empir-
ical null distribution from a set of test statistics [16]. In
order to compare the performance of those methods with
our Bayesian method, sets of test statistics were gener-
ated, similar to the approach described above, but under
different scenarios: scenario “equal” with equal propor-
tion of positive and negative associations (0.05, 0.05),
scenario “skewed” with only positive associations (prop.
0.1), scenario “small” similar to scenario equal with only
0.01 proportion of true associations, and scenario “close”
where the distribution for the means had expected value
of 1 (instead of 3). For each scenario, 2000 test statis-
tics were generated 100 times. To estimate the empirical
null distributions as proposed by Efron, we used the locfdr
R package. For both methods, maximum likelihood and
moment matching, default parameter settings were used
(Additional file 3).
Simulation with unobserved confounding factors
We used the simulation setup of Wang et al. [17] to gen-
erate data with confounding factors. Briefly, data Yn×p for
n = 100 samples and p = 2000 features were gener-
ated according to the following model: Yn×p = Xn×1βT +
Zn×rγ T + E, where Z, represents the r = 5 unobserved
confounding factors model as Z|X = XαT + D, with α
representing the strength of confounding. Furthermore, a
continuous covariate of interest, X, was sampled from the
normal distribution. Effects were introduced by fixing 90%
of the βs at zero while the remaining were different from
zero. Both E and D represent Gaussian noise. A detailed
description of the simulation setup is given by Wang et
al. and is available as an R function gen.sim.dat from the
package CATE (Additional file 3: section 5).
Simulation with correlated test statistics
Correlated test statistics were generated according to the
approach of Efron [51] introducing a block-correlation
structure among test statistics. The uncorrelated test
statistics with effects generated from the normal mixture
were added to the test statistics with block-correlation
structure (Additional file 3: section 3.3 and section 5). The
same number of repeated simulations, 100, number of test
statistics, 2000, and proportion of null features, 0.9 were
used.
The Gibbs sampler
We assume the observed set of test statistics can be
modeled by a three-component normal mixture:








with 9 − 1 parameters (the mixture proportions are con-
strained to sum to one,
∑3
j=1 j = 1), and φ(x;μj, σj)
being the density of N (μj, σ 2j ). Furthermore, one com-
ponent represents the empirical null distribution with its
estimated mean (i.e., bias) and standard deviation (i.e.,
inflation). We propose to use a Gibbs sampling algorithm
[31, 52, 53] to estimate the parameters of the mixture
distribution.
Conjugate prior distributions are used for the means,
μj, variances, σ 2j , and mixture proportions, j. Hence,
we assume a normal distribution, μj|σ 2j ∼ N (λj, σ 2j /τj),
for the means, an inverse gamma distribution, σ 2j ∼
IG(αj,βj), for the variances, and a Dirichlet distribution,
(1, 2, 3) ∼ D(γ1, γ2, γ3), for the mixture proportions.
Well chosen hyper-priors ensure that the occurrence of
labeling switching isminimized; i.e., during sampling from
the posterior, the null component is switched with one
of the alternative components. That is, we take informa-
tive hyper-priors for means, the null component, λ1 = 0,
and for the alternative components λ2 = −3 and λ3 = 3
all τ ’s are equal to 100. The hyper-priors for the vari-
ance parameters are equal for all components α = 1.28
and β = 0.36 and were taken from Raftery [54]. For the
Dirichlet distribution, widely used uniform noninforma-
tive prior parameters were chosen: γ1 = γ2 = γ3 = 1.
Furthermore, data-dependent starting values are used to
start the algorithm at a good initial point. These are based
on the median and median absolute deviation (MAD) of
the test statistics. A burn-in period of 3000 iterations was
used as well as 2000 subsequent samples to estimate the
parameters of the mixture distribution using the mean.
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Given test statistics xi (z-scores or transformed to
z-scores) for i = 1, · · · , p, prior distributions with hyper-
parameters, and starting values for the posterior distribu-
tions, the Gibbs sampling algorithm is run in the following
way:
Iterate for t = 1, · · · , 5000,
1. Generate the missing (unobserved) data:
zij ∼ M(p˜ij) from a multinomial distribution, with
parameter pij = jφ(xi;μj, σj), p˜ij represents the
normalized proportion
(∑3
j=1 = p˜ij = 1
)
.





i=1 y2i 1(zij =0)
3. Generate samples from the posteriors according to:
j ∼ D(γj + nj),
μj|σ 2j ∼ N
(
λjτj + sj
nj + τj ,






α+ 12 (nj + 1),
(







The latter mimics sampling from an inverse gamma dis-
tribution. For clarity, an iteration superscript is omitted.
We assume that 3000 iterations (burn-in period) are suffi-
cient for the Markov properties to hold and that the sam-
ples from the conditional distributions can be assumed
to be samples from the joint parameter distribution. We
implemented the Gibbs sampling algorithm in C and can
either use weighted multinomial sampling method for
binned test statistics or a fast sampling method [55] if all
individual test statistics are used (user-defined). Option-
ally, test statistics following a distribution different from
the normal distribution can be used by transforming them
to z-scores. For example, test statisticsw1, · · · ,wp that fol-
low under the null hypothesis a χ2-distribution with ν
degrees of freedom can be transformed to z-scores using
−1(Fχ2ν (wi)) [16] (Additional file 3).
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